Vertex Pharmaceuticals reports underwriters purchase additional stock at 38.50 per share

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters of its public offering have exercised in full their option to purchase an additional 1,500,000 shares of common stock at the public offering price of $38.50 per share. The exercise of the option brings the total shares of common stock sold by Vertex in the offering to 13,000,000 shares. Vertex expects to receive total gross proceeds from the offering, before commissions and expenses, of $500.5 million.

Goldman, Sachs & Co. is acting as the sole book-running manager for the offering, with BofA Merrill Lynch, J.P. Morgan Securities Inc., and Morgan Stanley & Co. Incorporated acting as co-managers.